Key result
Continuous-infusion homoharringtonine yields ~3% complete remission in refractory acute myelogenous leukemia.
Answers are grounded in this paper and cite their sources.
Thirty-one patients with a diagnosis of refractory acute myelogenous leukemia received homoharringtonine as their first (15 patients) or second (16 patients) salvage therapy. Homoharringtonine was given as a continuous infusion of 2.5 mg/m2 daily for 15 to 21 days to 13 patients (schedule 1), and of 3.0 mg/m2 daily for 15 days in 18 patients (schedule 2). Overall, one patient achieved complete remission (3%), and three (10%) had a hematologic improvement with normalization of the marrow and peripheral blood picture except for persistent thrombocytopenia. Six patients (19%) demonstrated prolonged myelosuppression, three (23%) on schedule 1 and three (17%) on schedule 2. Cardiovascular complications were minimal consisting of hypotension in one patient (3%) and supraventricular arrhythmias in two patients (6%). Hyperglycemia was observed in 42% of patients and was significant in 10%. The authors conclude that homoharringtonine, at the dose schedule investigated, has definite but low antileukemic efficacy. The low-dose continuous infusion schedule was associated with prolonged myelosuppression but no serious cardiovascular complications. The role of such therapy in myeloproliferative disorders, especially chronic myelogenous leukemia, deserves consideration.
No takes yet. Share an insight, caveat, or question.
Kantarjian et al. (1989) studied refractory acute myelogenous leukemia (n=31). Homoharringtonine was evaluated on Complete remission. Low-dose continuous infusion homoharringtonine resulted in a 3% complete remission rate and 10% hematologic improvement in patients with refractory acute myelogenous leukemia.
Synapse has enriched 10 related papers. Consider them for comparative context: